# Diabetes Research Hub — Monitor Report

**Generated:** 2026-05-30
**Run type:** Scheduled automated review (diabetes-hub-monitor)
**Hub root:** `C:\Users\justi\OneDrive\Diabetes_Research`
**Prior monitor report:** `monitor_report_2026-05-29.md`

---

## File System Status

Latest script outputs (all from `Analysis/Results/`):

| File | Last Modified | Age | Status |
|---|---|---|---|
| `hub_monitor_report.md` | 2026-05-30 07:05 | 0 d | Fresh |
| `clinical_trials_latest.json` | 2026-05-30 07:04 | 0 d | Fresh |
| `pubmed_recent_latest.json` | 2026-05-30 07:05 | 0 d | Fresh |
| `literature_gap_report.md` | 2026-05-29 08:08 | 1 d | Fresh |
| `literature_gap_data.json` | 2026-04-20 15:35 | **~40 d** | **STALE** |
| `agent_state.json` | 2026-05-29 08:10 | 1 d | Fresh |
| `citation_validation.json` | 2026-05-29 08:09 | 1 d | Fresh |

Total tracked files in hub: **880** (from `hub_monitor_report.md`). The hub_monitor.py scan reported **657 result file(s) older than 14 days** — but most are historical daily snapshots, which is expected.

**Action flag:** `literature_gap_data.json` underlying data is ~40 days old even though the human-readable report was regenerated yesterday. The report's narrative is fresh; the cross-tab counts behind it are not. Consider re-running `project1_literature_gap_analysis.py` to refresh the raw matrix.

---

## Clinical Trial Changes

Snapshot diff vs. 2026-05-23 (7-day window):

- Total trials: 797 → **804** (+7 net)
- New trials added: **7**
- Status changes: **9**
- Newly posted results: **1**

### New trials (last 7 days)

| NCT | Phase | Status | Sponsor | Title (truncated) |
|---|---|---|---|---|
| NCT07613307 | PHASE3 | NOT_YET_RECRUITING | Eli Lilly | Orforglipron (LY3502970) in T2D |
| NCT07614412 | PHASE2 | NOT_YET_RECRUITING | Saudi MoH | SHIELD-T1D: Shingrix + GLP-1 for Beta-Cell Preservation |
| NCT07611721 | NA | RECRUITING | Inst. for Clinical and... | Dexcom G7 CGM performance |
| NCT04426474 | PHASE1 | COMPLETED | Eli Lilly | LY3502970 (orforglipron) in T2D |
| NCT07613489 | NA | ACTIVE_NOT_RECRUITING | Univ. of Faisalabad | Photobiomodulation for diabetic peripheral neuropathy |
| NCT07610213 | PHASE1 | NOT_YET_RECRUITING | Abdullah Kars | Sequential immune modulation + antigen-specific tolerance |
| NCT03242343 | NA | COMPLETED | Laminate Medical | VasQ external support for AV fistula (renal) |

**Key new entries to track:**
- **NCT07613307** — new Eli Lilly Phase 3 of **orforglipron** in T2D (relevant to FDA's recent Foundayo approval; track for primary endpoints).
- **NCT07614412** — SHIELD-T1D combines Shingrix + GLP-1 for beta-cell preservation in recent-onset T1D; novel mechanism worth flagging.

### Status changes (last 7 days)

| NCT | Change | Notes |
|---|---|---|
| NCT07564414 | NOT_YET_RECRUITING → RECRUITING | Novo Nordisk **CagriSema** (n=2,500) — major Phase 3 now enrolling |
| NCT07599982 | NOT_YET_RECRUITING → RECRUITING | MODI insulin titration algorithm safety study |
| NCT07527650 | NOT_YET_RECRUITING → RECRUITING | HM15275 in T2D |
| NCT07284511 | NOT_YET_RECRUITING → RECRUITING | Tirzepatide in T1D |
| NCT05754281 | RECRUITING → ACTIVE_NOT_RECRUITING | LabPatch glucose-sensing PRECISION II |
| NCT07408141 | RECRUITING → ACTIVE_NOT_RECRUITING | MiniMed Fit Payload Wear Study |
| NCT06888687 | RECRUITING → ACTIVE_NOT_RECRUITING | Dietetics + CGM comparison |
| NCT06728059 | RECRUITING → COMPLETED | ML bolus priming for closed-loop (results posted same day) |
| NCT07124208 | RECRUITING → NOT_YET_RECRUITING | Biophoton therapy for T2D (status regression — minor) |

### Recently posted results

- **NCT06728059** (results posted 2026-05-28) — Safety and feasibility of a machine-learning bolus priming added to existing closed-loop systems. Worth reviewing for the AI/ML + Closed Loop intersection.

### Key Phase 3 trials currently RECRUITING (top 5 by enrollment)

| NCT | n | Sponsor | Intervention |
|---|---|---|---|
| NCT07064473 | 11,800 | Boehringer Ingelheim | Vicadrostat (BI 690517) combo — EASi-PROTKT |
| NCT07481747 | 2,539 | Hudson Biotech | Tirzepatide vs placebo |
| NCT07564414 | 2,500 | Novo Nordisk | **CagriSema** (just moved to RECRUITING) |
| NCT06082063 | 2,000 | Steno Diabetes Center | Multifactorial CV-risk in T1D |
| NCT07351058 | 1,600 | Roche | Enicepatide (RO7795068) |

### Key-organization coverage

- **Vertex:** 3 trials, including **VX-880 Phase 3** (NCT06832410, RECRUITING) and follow-on **VX-880** (NCT04786262, RECRUITING) + **VX-264** Phase 1/2 active. *Note: zimislecel = VX-880; the trial DB still uses the trade ID rather than the INN.*
- **Eli Lilly:** 29 trials. Notable: **baricitinib** in T1D (NCT07222137 & NCT07222332, both Phase 3 RECRUITING), **tirzepatide** in T1D long-term (NCT06962280), plus new **orforglipron** Phase 3 (NCT07613307).
- **Novo Nordisk:** 26 trials. **CagriSema** now in Phase 3 RECRUITING; **insulin icodec** Phase 3 (NCT07076199); two oral semaglutide Phase 3s.
- **Sana Biotechnology:** 0 trials registered (track separately; their hypoimmune-islet program is preclinical/early phase and may post under partner sponsors).

---

## PubMed Highlights

Snapshot diff vs. 2026-05-23 (7-day window):

- Total unique papers: 150 → **164** (164 in the 30-day lookback window)
- New papers in window: 111
- Papers dropped from window: 97

### Cross-domain papers (14 total — highest priority)

These appear in ≥2 alert domains and represent the highest-value reads:

| PMID | Domains | Title |
|---|---|---|
| 42163482 | T1D Stem Cell Cure × T1D Immunotherapy × **teplizumab** | Assessing Extracellular Vesicle Proteins as Predictive Biomarkers for Developing Type 1 Diabetes |
| 42148104 | T1D Stem Cell Cure × T1D Immunotherapy | Adapting CAR-T and CAR-Treg cancer therapies for autoimmunity |
| 42138126 | T1D Immunotherapy × **teplizumab** | US Patterns in Clinical Islet Autoantibody Ordering |
| 42138080 | T1D Immunotherapy × **teplizumab** | New and emerging therapies in type 1 diabetes |
| 42208956 | T2D GLP-1 New × **retatrutide** | Beyond weight loss: multisystem benefits of obesity medications |
| 42199793 | T2D Remission × **dapagliflozin** | Dapagliflozin + linagliptin combo reverses hepatic insulin resistance |
| 42208537 | Diabetes AI/ML × Gene Therapy | Capturing multi-disease states on a spectrum with ML and routine clinical data |
| 42206849 | Diabetes AI/ML × Microbiome | Early-life proteomic and microbiome features signal obesity risk (26-yr follow-up) |
| 42209585 | Biomarker × Complications New | Thrombin in diabetic retinal pathology (STZ mice) |
| 42208844 | Biomarker × Complications New | Proteomic meta-analysis in proliferative diabetic retinopathy |
| 42211453 | Microbiome × Multi-Omics | Gut microbiota–diabetic peripheral neuropathy bibliometric mapping |
| 42199945 | Epigenetics × Multi-Omics | Mendelian randomization on glycolipid metabolism in diabetes |
| 42198313 | **orforglipron × retatrutide × CagriSema** | Diabetes & stroke: pathophysiology + GLP-1/incretin therapies |
| 42142983 | **retatrutide × CagriSema** | Bariatric surgery weight-loss audit (regional) |

### Key-therapy mention counts (30-day window)

| Therapy | Mentions in window |
|---|---|
| dapagliflozin | 45 |
| retatrutide | 9 |
| teplizumab | 5 |
| CagriSema | 5 |
| icodec | 5 |
| baricitinib | 4 |
| orforglipron | 4 |
| **zimislecel** | **0** |

Zimislecel has zero literature mentions in the 30-day window — most likely because the field still indexes the molecule under "VX-880." Consider adding `"VX-880"` as a synonym in `baseline_pubmed_alerts.py` to avoid missing relevant work.

### Domain volume notes

- Highest activity (30-day): **Diabetes AI/ML** (244 total hits), **Biomarker** (179), **Microbiome** (157), **T2D GLP-1 New** (140).
- Smallest: **GLP-1 Pharmacogenomics** (2), **Drug Repurpose** (7), **LADA New Research** (8) — these correlate with the Tier-1 gap intersections below.

---

## Gap Analysis Summary

(From `literature_gap_report.md`, generated 2026-05-29.) Top 5 under-researched intersections with plausible scientific rationale (Gap Score = 100.0; BRONZE-validated):

1. **Beta Cell Regen × Health Equity** — no joint pubs; access analysis for regenerative therapies absent.
2. **Insulin Resistance × Islet Transplant** — 1 joint pub; affects graft survival but barely studied.
3. **Islet Transplant × Drug Repurposing** — 0 joint pubs; existing immunosuppressants could be screened computationally for islet protection.
4. **Islet Transplant × Health Equity** — 0 joint pubs; islet transplant centers are geographically concentrated.
5. **Gene Therapy × LADA** — 0 joint pubs; autoimmune mechanism makes LADA a candidate.

**Alignment with Tier 1 contribution areas (per RESEARCH_DOCTRINE / CONTRIBUTION_STRATEGY):**

- Gaps #3 (Islet Transplant × Drug Repurposing) and #1 (Beta Cell Regen × Health Equity) align directly with the existing **Drug Repurposing Islet** and **Trial Equity Mapper** dashboards — they're ready-made publication seeds.
- Gap #5 (Gene Therapy × LADA) aligns with the **LADA Diagnostic Model** dashboard and is a strong candidate for a brief perspective/letter.

**Caveat (per Research Doctrine):** All gap scores are BRONZE — they should be validated by querying combined-keyword PubMed searches and cross-checking PROSPERO/Cochrane before publishing claims.

---

## Breaking News (web check, last ~7 days)

Material items only:

- **Eli Lilly TRIUMPH-1 (retatrutide) Phase 3 topline** — 12 mg arm achieved **avg. 28.3% weight loss over 80 weeks**; 45.3% of participants ≥30% weight loss. Already widely covered (PRNewswire / AJMC). TRIUMPH-2 (T2D) and TRIUMPH-3 (CVD) read-outs expected later in 2026. *Evidence level: Topline press release — SILVER (peer-reviewed publication pending).* This pairs with the cross-domain PubMed hit #42208956 above.
- **FDA — orforglipron (Lilly Foundayo)** approved (already reflected in the dashboard); first GLP-1 pill not requiring food/water restrictions. Date precedes 7-day window but provides context for the new NCT07613307 Phase 3 entry.
- **Pending FDA decision: Afrezza pediatric label expansion** — PDUFA **May 29, 2026** (yesterday). No public approval/CRL notice surfaced in the search; check FDA newsroom directly for the official action.
- **Awiqli (insulin icodec)** previously approved (March 26, 2026) — context for NCT07076199 (Novo Phase 3 insulin icodec, recruiting).

No new Phase 3 read-outs or FDA actions beyond the above were surfaced in the 7-day search window.

---

## Recommended Actions

1. **Refresh gap-analysis raw data.** Run: `python project1_literature_gap_analysis.py` — `literature_gap_data.json` is ~40 days old while the human report was regenerated yesterday.
2. **Add VX-880 synonym to PubMed alerts.** Edit `baseline_pubmed_alerts.py` to include `"VX-880" OR "zimislecel"` so the zero-mention metric isn't an indexing artifact.
3. **Update the Tracker** (`Diabetes_Research_Tracker.xlsx`) with the 7 new trials, especially **NCT07613307 (orforglipron Phase 3)**, **NCT07614412 (SHIELD-T1D)**, and the **CagriSema** status flip to RECRUITING (NCT07564414).
4. **Review cross-domain paper PMID 42163482** — EV proteins as T1D biomarkers, sits at Stem Cell Cure × Immunotherapy × teplizumab. Highest-value read this week.
5. **Verify the Afrezza pediatric PDUFA outcome** (decision was due 2026-05-29). Check FDA.gov directly; if approved, add to the device/insulin tracking and to the T1D youth dashboard.
6. **Pull and review NCT06728059 results** (ML bolus priming for closed-loop) — first newly-posted results in this snapshot and methodologically relevant to the AI/ML × Closed Loop dashboard.
7. **Confirm baricitinib Phase 3 enrollment is on track** — NCT07222137 and NCT07222332 remain RECRUITING; no status change this week. Per TrialNet preliminary findings (baricitinib slows T1D progression), these are pivotal trials worth a tracker note.
8. **No file changes were made on this run** — this report is the only new file (per task rules).

---

*Generated by diabetes-hub-monitor scheduled task — automated review of script outputs only; no source files modified.*

**Sources (web check):**

- [Retatrutide Achieves Up to 30.3% Weight Loss in Phase 3 TRIUMPH-1 — AJMC](https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial)
- [Lilly's retatrutide TRIUMPH-1 — PRNewswire](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html)
- [FDA Approves Lilly's Foundayo (orforglipron)](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill)
- [Novo Nordisk Awiqli (insulin icodec) FDA approval](https://finance.yahoo.com/sectors/healthcare/articles/novo-nordisks-awiqli-gets-fda-160800600.html)
- [FDA Drug Approval Decisions Expected in May 2026 — Cardiology Advisor](https://www.thecardiologyadvisor.com/news/fda-drug-approval-decisions-expected-in-may-2026/)
- [Baricitinib slows T1D progression — TrialNet](https://www.trialnet.org/events-news/blog/study-finds-jak-inhibitor-baricitinib-slows-t1d)
